Urology news for Tuesday, October 27, 2026

Top 5 in urology

Perioperative nivolumab plus chemotherapy misses co-primary endpoints in muscle-invasive bladder cancer Study · OncLive · 2026-10-23
This phase 3 trial testing neoadjuvant chemotherapy plus nivolumab followed by adjuvant nivolumab against chemotherapy alone in muscle-invasive bladder cancer did not meet its co-primary endpoints. The negative result contrasts with other perioperative immunotherapy regimens that have shown benefit in this disease setting.
Why it matters: This negative randomized trial indicates that not all perioperative immunotherapy combinations improve outcomes in muscle-invasive bladder cancer, and it contrasts with positive results from other regimens presented at…
More Bladder cancer news
FDA approves talazoparib plus enzalutamide for HRR gene-altered metastatic prostate cancer FDA approval · CancerNetwork · 2026-10-26
The FDA approved the combination of talazoparib and enzalutamide for patients with HRR gene-altered metastatic prostate cancer, expanding use of the PARP inhibitor-antiandrogen combination to an earlier treatment setting.
Why it matters: Provides an additional approved option for HRR-mutated metastatic prostate cancer patients, relevant to treatment sequencing decisions.
More Prostate cancer news
APCCC 2026 panel reaches consensus on only a third of questions in high-risk/recurrent prostate cancer Guideline · Eur Urol · 2026-10-27
An international 133-member expert panel voted on 134 questions regarding high-risk localized, locally advanced, and biochemically recurrent prostate cancer; consensus (≥75% agreement) was reached on only 44 questions (33%), with strong consensus (≥90%) on 7.
Why it matters: Highlights the many areas of management, including PSA persistence and recurrence, where high-level evidence is still lacking and practice varies among experts.
More Prostate cancer news
Adding visugromab to nivolumab raises pathologic complete response in small MIBC trial Phase 1-2 · Nat Med · 2026-10-26
In the nonrandomized, placebo-controlled phase 2a GDFATHER-NEO trial of 31 cisplatin-ineligible/refusing MIBC patients, neoadjuvant nivolumab plus the GDF-15 antibody visugromab yielded 33% pathologic complete response (5 of 15 evaluable) versus 8% (1 of 13) with nivolumab plus placebo, with no treatment-related delays to surgery.
Why it matters: Early signal in a small, nonrandomized exploratory trial suggests GDF-15 blockade may enhance neoadjuvant checkpoint inhibition in MIBC, warranting larger randomized confirmation.
More Bladder cancer news
Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
More Upper tract urothelial carcinoma news

Prostate cancer news

Low-risk prostate cancer diagnoses and radiation use have steadily declined since 2010, registry data show Retrospective · Cancer · 2026-10-27
Across SEER, VA, and a Michigan radiation quality consortium, low-risk disease fell from 28.8% to 24.0% of localized diagnoses (SEER) and treatment avoidance in low-risk patients rose from 33.6% to 83.4% (SEER); among radiation-treated patients, the low-risk share dropped from 33.7% to 6.5% (SEER).
Why it matters: Raises the question of how diagnostic shifts and wider active surveillance uptake are together reducing radiation use in low-risk disease across settings.
J&J reports 75% tumor response rate with novel RIPTAC molecule JNJ-6143 in mCRPC Phase 1-2 · UroToday · 2026-10-25
Johnson & Johnson reported a 75% tumor response rate for JNJ-6143, a first-in-class RIPTAC molecule, in an early-phase study in advanced prostate cancer.
Why it matters: Early single-arm data on a new drug class in mCRPC, not yet confirmatory of survival benefit.
ENZARAD: Enzalutamide added no MFS or OS benefit over older antiandrogen with ADT/RT Phase 3 RCT · J Clin Oncol · 2026-10-25
In this phase 3 trial of 802 men with high-risk localized/locally advanced prostate cancer, adding enzalutamide for 24 months to ADT and radiotherapy did not significantly improve 8-year metastasis-free survival versus an older nonsteroidal antiandrogen given for 6 months (74% vs 72%, HR 0.88, P=0.34).
Why it matters: A negative phase 3 trial in a setting where other AR-pathway inhibitors (eg darolutamide) have shown benefit, underscoring that agents and regimens are not interchangeable.
J&J: Perioperative apalutamide plus ADT cuts recurrence/death risk 62% vs surgery alone Study · The Manila Times · 2026-10-24
Johnson & Johnson announced topline results from a phase 3 trial showing apalutamide plus ADT given before and after radical prostatectomy reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer. Full data have not yet been published or peer-reviewed.
Why it matters: New prostate cancer drug combo may cut cancer return risk by more than half before and after surgery. J&J reports a hormone-blocking pill, apalutamide, used before and after prostate removal lowered cancer return or…
Gedatolisib plus darolutamide shows early activity in metastatic castration-resistant prostate cancer Phase 1-2 · Urology Times · 2026-10-23
An early-phase study reported preliminary anti-tumor activity when combining the PI3K/mTOR inhibitor gedatolisib with darolutamide in men with metastatic castration-resistant prostate cancer.
Why it matters: Early-phase combination data are hypothesis generating and would need randomized confirmation before changing practice.
Darolutamide plus ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer Study · company release · The Manila Times · 2026-10-24
A phase 3 trial found that adding darolutamide to ADT and radiation therapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone in men with prostate cancer at high risk of recurrence.
Why it matters: A phase 3 trial found darolutamide plus ADT and radiation cut metastasis or death risk, which can be considered in high-risk recurrent prostate cancer pending full details.
Updated CAPItello-281 analysis shows OS benefit with capivasertib-abiraterone in PTEN-deficient mHSPC Retrospective · Ann Oncol · 2026-10-24
In an ad hoc, non-prespecified descriptive analysis of the phase 3 CAPItello-281 trial at 42% survival data maturity (median follow-up 39 months), capivasertib plus abiraterone showed an overall survival benefit over placebo plus abiraterone in PTEN-deficient de novo mHSPC (median 57.4 vs 46.5 months, HR 0.82, 95% CI 0.68-0.99, P=0.044), consistent with the updated radiographic progression-free survival benefit (HR…
Why it matters: A descriptive, non-prespecified interim update suggests a survival benefit in PTEN-deficient mHSPC; results are from an ad hoc analysis, not a prespecified final analysis.
Global prostate cancer cases projected to nearly double by 2050, GLOBOCAN review finds Review · Eur Urol · 2026-10-24
A GLOBOCAN-based review estimates 1.55 million new prostate cancer cases and 420,000 deaths worldwide in 2024, projecting 2.88 million cases and 924,000 deaths by 2050, with the largest relative mortality rise in Africa. The review also summarizes known risk factors including family history, germline variants, and smoking.
Why it matters: Highlights substantial and growing global disparities in prostate cancer burden tied to screening access and care equity.

Bladder cancer news

Durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) cuts death risk 42% in bladder cancer trial Study · The Pharmaletter · 2026-10-26
A trial of durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) reported a 42% reduction in death risk in bladder cancer, though the report notes it trails the pembrolizumab (Keytruda)-based combination.
Why it matters: Adds a second checkpoint-inhibitor/ADC combination with a reported survival benefit in advanced urothelial cancer, though cross-trial comparisons are not definitive.
VOLGA: perioperative durvalumab plus enfortumab vedotin improves EFS and OS in cisplatin-ineligible MIBC Phase 3 RCT · N Engl J Med · 2026-10-24
In 695 patients with MIBC who were cisplatin-ineligible or declined cisplatin (median follow-up 23 months), perioperative durvalumab plus neoadjuvant enfortumab vedotin improved event-free survival versus upfront cystectomy (HR 0.51, 95% CI 0.38 to 0.67; 24-month EFS 64% vs 45%) and overall survival (HR 0.58; 24-month OS 78% vs 69%). pCR was 45% vs 10%. Adding tremelimumab improved EFS (HR 0.61) but not OS at this interim analysis.
Why it matters: Supports perioperative enfortumab vedotin with checkpoint blockade for patients who cannot receive or decline cisplatin; the FDA has granted the doublet priority review.
Hautmann and modified Studer neobladders show similar complication rates, but outlet obstruction differs Retrospective · BJU Int · 2026-10-25
In a propensity-matched comparison of 208 patients after radical cystectomy with orthotopic neobladder, overall urinary diversion complications were similar between Hautmann and modified Studer configurations, but outlet obstruction and 90-day readmission were more common with modified Studer (OR 2.99 and 1.87 respectively).
Why it matters: Retrospective single-center comparison; raises the question of configuration-specific obstruction risk but needs validation before changing reconstructive choice.
KEYNOTE-866: Perioperative pembrolizumab did not significantly improve event-free survival in cisplatin-eligible MIBC Phase 3 RCT · Ann Oncol · 2026-10-24
In this phase 3 trial of 907 cisplatin-eligible MIBC patients, adding perioperative pembrolizumab to neoadjuvant cisplatin-gemcitabine did not significantly improve 5-year event-free survival (63.5% vs 61.9%, HR 0.88) despite a higher pathologic complete response rate (44.4% vs 35.8%).
Why it matters: Contrasts with other perioperative immunotherapy regimens that have shown benefit in MIBC, highlighting that pCR gains do not always translate to survival benefit.
Final CA017-078 results: perioperative nivolumab plus chemo did not improve event-free survival in MIBC Phase 3 RCT · Ann Oncol · 2026-10-24
In this phase 3 trial of 653 patients with resectable MIBC, neoadjuvant nivolumab plus gemcitabine-cisplatin followed by adjuvant nivolumab improved pathologic complete response (39.1% vs 29.6%) but did not improve event-free survival compared to chemotherapy alone (HR 0.94) at a median follow-up of 54.5 months.
Why it matters: Adds to a mixed body of phase 3 evidence on perioperative checkpoint inhibition in MIBC, where pCR gains have not uniformly translated into event-free survival benefit.
ctDNA prognostic regardless of therapy received in cisplatin-eligible MIBC Retrospective · CancerNetwork · 2026-10-23
An analysis found circulating tumor DNA status was prognostic for outcomes irrespective of the perioperative therapy given in cisplatin-eligible muscle-invasive bladder cancer, according to the source headline.
Why it matters: Raises the question of ctDNA as a general prognostic biomarker in MIBC, though it does not establish predictive utility for selecting therapy.
Initial enfortumab vedotin dose reduction not clearly linked to worse survival in pretreated urothelial cancer Retrospective · JAMA Netw Open · 2026-10-23
In a multicenter Korean cohort of 368 patients with pretreated advanced urothelial carcinoma, physician-selected initial dose reduction of enfortumab vedotin showed no statistically significant difference in progression-free or overall survival compared with full dose, though confidence intervals were wide.
Why it matters: Raises the question of whether upfront dose reduction can preserve outcomes in selected patients, but this retrospective comparison cannot establish equivalence.
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC Intl regulatory · Urology Times · 2026-10-21
The European Commission approved the combination of perioperative pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer.
Why it matters: Adds a European regulatory pathway for a perioperative immunotherapy-ADC combination in MIBC, aligning with prior approvals in other regions.
Meta-analysis finds no significant survival difference for bladder-sparing vs early cystectomy in cT1 micropapillary cancer Meta-analysis · Eur Urol Oncol · 2026-10-21
Pooled data from 9 retrospective studies (1033 micropapillary cases) showed no statistically significant difference in cancer-specific survival between bladder-sparing approaches (mostly BCG) and early radical cystectomy for cT1 micropapillary urothelial carcinoma.
Why it matters: Raises the question of whether selected cT1 micropapillary patients could be managed with bladder-sparing therapy, but retrospective pooling limits causal inference.

Kidney cancer news

BMJ review summarizes current standards and gaps in renal cell carcinoma management Review · BMJ · 2026-10-27
A narrative review covers molecular subtyping, imaging-based diagnosis, surgical options including partial nephrectomy and ablation, adjuvant pembrolizumab for high-risk disease, and checkpoint inhibitor combinations in metastatic RCC, while noting resistance and lack of biomarkers remain challenges.
Why it matters: Offers a concise overview of the current RCC treatment landscape for clinicians outside subspecialty practice.
Xencor selects phase 3 dose for XmAb819 after 45.5% response rate in RCC Phase 1-2 · TradingView · 2026-10-26
XmAb819, a bispecific antibody, showed a 45.5% objective response rate in a kidney cancer trial, prompting selection of a phase 3 dose.
Why it matters: Early efficacy signal for a novel bispecific in RCC, though single-arm data require phase 3 confirmation.
Adding belzutifan or quavonlimab to pembrolizumab-lenvatinib fails to improve PFS or OS in RCC Phase 3 RCT · Ann Oncol · 2026-10-26
In the phase 3 LITESPARK-012 trial, adding belzutifan or quavonlimab/pembrolizumab to pembrolizumab plus lenvatinib did not improve PFS or OS versus pembrolizumab-lenvatinib alone in first-line advanced clear-cell RCC.
Why it matters: Confirms pembrolizumab plus lenvatinib remains the standard first-line regimen; these additions did not improve outcomes.
Belzutifan-lenvatinib keeps PFS and response edge over cabozantinib in RCC, OS not significant Phase 3 RCT · Ann Oncol · 2026-10-26
Final LITESPARK-011 analysis in previously treated advanced clear-cell RCC shows belzutifan plus lenvatinib maintained PFS (HR 0.74) and response rate benefits over cabozantinib, but mature OS (HR 0.85) did not cross the prespecified significance boundary.
Why it matters: Supports belzutifan-lenvatinib as an option after anti-PD-(L)1 therapy for PFS and response, though OS benefit remains unproven.
Non-interventional management of small renal masses under 2cm rose from 8% to 24% over 2004-2022, SEER shows Retrospective · Urology · 2026-10-25
In a SEER analysis of 20,769 patients with renal masses under 2cm (2004-2022), non-interventional management rose from 8.0% to 23.9%, with the largest increases in patients 70 and older (22.0% to 45.9%) and African American patients (4.5% to 23.2%). Five-year cancer-specific mortality remained stable at about 2.8%-2.9%.
Why it matters: Hypothesis-generating registry data lacking comorbidity and shared decision-making detail, not evidence that surveillance is equivalent to treatment for all patients.
Phase 3 trial opens testing benmelstobart-anlotinib vs sunitinib in non-clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-20
A phase 3 trial will randomize 126 patients with advanced non-clear cell renal cell carcinoma (excluding chromophobe, collecting duct, and medullary subtypes) 2:1 to benmelstobart plus anlotinib versus sunitinib, with progression-free survival as the primary endpoint.

Upper tract urothelial carcinoma news

UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08
Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).
Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.

Endourology and stone disease news

Commentary: why the PUSH hydration trial found no benefit despite decades of stone prevention advice Commentary · Kidney Int · 2026-10-22
A commentary on the PUSH trial (n=1658) notes its behavioral hydration intervention did not significantly reduce stone recurrence, likely due to poor adherence and only a minimal urine volume difference versus controls, contrasting with the 1996 Borghi trial where sustained high urine output did reduce recurrence.
Why it matters: Suggests that advising hydration alone without structured adherence support may not translate into the urine volume increases needed for stone prevention.
Meta-analysis: no overall SFR difference between primary and delayed ureteroscopy for obstructing stones Meta-analysis · Eur Urol Open Sci · 2026-10-21
Pooled data from 15 studies (19,907 patients) found no significant difference in stone-free rates between primary ureteroscopy (within 24-48 hours) and delayed ureteroscopy (OR 1.20, 95% CI 0.75-1.92, I2=86%). In a subgroup of 5 studies using a zero-fragment imaging definition, primary URS had higher odds of stone-free status (OR 1.49, 95% CI 1.10-2.02); a sensitivity analysis of 2 CT-based trials with strict…
Why it matters: Supports flexibility in ureteroscopy timing overall, but the zero-fragment subgroup signal favoring primary URS stems from few studies and needs confirmation given heterogeneity in the full analysis.

BPH and male LUTS news

Bipolar enucleation noninferior to TURP for 12-month symptom relief in RCT RCT · Eur Urol Focus · 2026-10-24
In an 84-patient two-center RCT, median 12-month IPSS was 5 in both bipolar enucleation (BipolEP) and TURP arms, meeting the noninferiority margin. BipolEP removed more tissue but had more early low-grade complications, while severe complications occurred only after TURP.
Why it matters: Supports BipolEP as an alternative to TURP for moderate-sized prostates with comparable symptom outcomes at one year.
Meta-analysis: early apical release technique reduces short-term incontinence after HoLEP Meta-analysis · Prostate Cancer Prostatic Dis · 2026-10-21
Pooling 5 studies (2821 patients), early apical release during HoLEP was associated with lower rates of stress incontinence at 4-6 weeks and 3-4 months versus conventional technique, with no difference by 6-12 months and similar functional outcomes overall.
Why it matters: Suggests early apical release may speed continence recovery after HoLEP without compromising later functional outcomes, pending confirmation in controlled trials.

Female pelvic medicine and neurourology news

FDA issues Class 2 recall of InterStim SureScan device FDA action · FDA · 2026-10-22
FDA has issued a Class 2 recall for the InterStim SureScan sacral neuromodulation system; specific defect and affected lots are detailed in the recall notice.
Why it matters: Providers implanting or following patients with InterStim SureScan devices should review the recall details for affected units.

Reconstruction and trauma news

Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14
A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…
Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.
Systematic review: incisional hernia after robotic prostatectomy varies widely, linked to extraction site Review · Eur Urol Open Sci · 2026-10-12
Across 16 mostly retrospective studies (56,661 patients), reported incisional hernia after minimally invasive radical prostatectomy ranged from 0.04% to 31%. Two comparative studies found lower rates with Pfannenstiel than periumbilical extraction, and three registry studies reported lower rates after open surgery than after MIRP. Evidence is limited by heterogeneous definitions and follow-up.
Why it matters: Observational data suggest specimen extraction site and surgical approach may influence incisional hernia risk after robotic prostatectomy, but evidence is heterogeneous and not yet definitive.
Augmentation cystoplasty shows durable urodynamic benefit over median 19 years in spinal cord injury Retrospective · BJU Int · 2026-10-10
In a retrospective cohort of 70 patients with spinal cord injury and refractory neurogenic bladder dysfunction, augmentation cystoplasty increased mean bladder capacity from 155 to 490 mL and reduced detrusor pressure from 72 to 19 cmH2O, with continence achieved in 67% over a mean 19-year follow-up; complications included urolithiasis (10%) and malignancy (4%).
Why it matters: Provides long-term reassurance on durability and complication rates for augmentation cystoplasty in a population with limited surgical alternatives.
Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.

Men's health news

Markov model suggests male-first evaluation may reduce cost and time to pregnancy in varicocele-related infertility Study · J Urol · 2026-10-24
A theoretical discrete-time Markov model comparing four infertility treatment strategies in couples with male varicocele found that male-first evaluation modestly reduced cost and time to pregnancy compared to current practice when repair efficacy was at least 5%, though immediate ART shortened time to pregnancy at 40-80% higher cost.
Why it matters: A modeling study, not clinical trial data, suggesting male-first evaluation could be cost-conscious in select varicocele-related infertility cases pending real-world validation.

Pediatric urology news

AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
Higher chemotherapy dose and testicular radiation linked to abnormal pubertal hormone patterns in childhood cancer survivors Retrospective · JAMA Netw Open · 2026-10-10
In a cohort of 221 male childhood cancer survivors, cumulative alkylating chemotherapy dose and testicular radiotherapy above 1 Gy were associated with dose-dependent elevations in pubertal FSH levels, a marker of impaired gonadal function.
Why it matters: Suggests cumulative alkylator and testicular radiation dose track with gonadal dysfunction, which may help identify survivors for earlier fertility discussions.
Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Raises the question of whether temporary vesicostomy reduces early complications after augmentation; retrospective comparison cannot exclude selection differences.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.

Infection, transplant and general urology news

Empagliflozin increased kidney volume without changing eGFR decline in ADPKD feasibility trial RCT · J Am Soc Nephrol · 2026-10-25
In a 50-patient randomized feasibility trial in autosomal dominant polycystic kidney disease, empagliflozin for 12 months was safe and tolerated, but was associated with a greater increase in total kidney volume than placebo, with no difference in chronic eGFR slope, vascular stiffness, or copeptin.
Why it matters: A pilot RCT suggesting SGLT2 inhibitors may not behave the same way in ADPKD as in diabetic or other CKD, despite proven benefit elsewhere; larger trials are needed before extrapolating.

Technology and AI news

NICE recommends five AI tools for prostate cancer screening pathways Intl regulatory · BMJ · 2026-10-24
The UK's NICE has recommended five artificial intelligence tools for use in prostate cancer screening pathways, according to a BMJ news report. Details on the specific tools, evidence base, and conditions of use were not specified in the available source.
Why it matters: UK health body NICE recommends five AI programs for use in prostate cancer screening pathways, per a BMJ report.

More urology news

No difference in complication or readmission rates by PA versus NP staffing after radical prostatectomy Retrospective · JU Open Plus · 2026-10-23
In a Medicare 20% sample of 8,975 men undergoing radical prostatectomy across 424 urology groups, postoperative complications, prolonged length of stay, and 90-day readmission did not differ significantly between practices staffed with PAs only, NPs only, or both.
Why it matters: Raises the question of whether PA and NP staffing models can be considered interchangeable for this operation, though this is hypothesis generating from Medicare claims data that lack clinical granularity.
Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16
A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.
Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.

Loading today's edition…